Reumatologia - postępy 2008Medycyna Praktyczna, PolandGolimumab, a new human anti-TNF-alpha monoclonal antibody administered subcutaneously every 4 weeks, improves anemia and well-being in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Ann. Rheum. Dis., 2008; 67 (supl. ... |